絞り込み

16241

広告

635件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Targeting EGFR T790M mutation in NSCLC: from biology to evaluation and treatment.

Brief report: EGFR L858M/L861Q cis mutations confer selective sensitivity to afatinib.

Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?

Comparable Clinical Outcomes in Patients with HER2-mutant and EGFR-mutant Lung Adenocarcinomas.

Effectiveness of afatinib in lung cancer with paralytic ileus due to peritoneal carcinomatosis.

Potential role of immunotherapy in advanced non-small-cell lung cancer.

Clinical Efficacy of Afatinib Treatment for a Patient with Leptomeningeal Carcinomatosis.

A phase II study of daily afatinib (BIBW 2992) with or without temozolomide (21/28 days) in the treatment of patients with recurrent glioblastoma.

A phase II trial of afatinib (BIBW 2992) in patients (pts) with advanced non-small cell lung cancer previously treated with erlotinib (E) or gefitinib (G).

Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib.

Phase II, open-label trial to assess the effect of continuous oral afatinib (BIBW 2992) at a daily dose of 50 mg on QTc, pharmacokinetics, and efficacy in relapsed or refractory solid tumors including brain metastases and glioblastoma that is not amenable to other therapy.

Phase I trial assessing safety and pharmacokinetics of afatinib (BIBW 2992) with intravenous weekly vinorelbine in advanced solid tumors.

Response to EGFR TKIs in never smokers with stage IV EGFR mutant squamous cell carcinoma of the lung (SQCC).

An autopsy case of bronchiolitis obliterans as a previously unrecognized adverse event of afatinib treatment.

Clinical Outcome of ALK -Positive Non-Small Cell Lung Cancer (NSCLC) Patients with de novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKI).

Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: a meta-analysis of clinical trials of gefitinib, erlotinib and afatinib in advanced EGFR-mutated non-small-cell lung cancer.

EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6.

Afatinib successfully treated leptomeningeal metastasis during erlotinib treatment in a patient with EGFR-mutant (Exon18:G719S) lung adenocarcinoma as a second-line chemotherapy.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
Sort by
※並べ替えは表示に時間がかかります